Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
surinabant · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | - |
| 2 | ACTIVE_COMPARATOR | surinabant 2,5 mg/day |
| 3 | ACTIVE_COMPARATOR | surinabant 5 mg/day |
| 4 | ACTIVE_COMPARATOR | surinabant 10 mg/day |
| Name | Type | Description |
|---|---|---|
| surinabant (SR147778) | DRUG | oral administration |
| placebo | DRUG | oral administration |
Inclusion Criteria: * Patients over legal age smoking at least 10 cigarettes/day as a mean within the 6 months preceding the screening visit. Exclusion Criteria: * Patients with a limited level of motivation. * Other participant in a household enrolled in the study. * Patients who have smoked or ...
Surinabant is an investigational small molecule being studied as an aid to smoking cessation. It is being developed by Sanofi for the treatment of nicotine dependence, with the goal of helping people quit smoking. The drug is currently in clinical development and has not been approved by regulatory authorities.
Surinabant is a small molecule that targets the cannabinoid receptor system, specifically acting as a CB1 receptor antagonist. By blocking CB1 receptors, it is thought to modulate the brain's reward pathways that contribute to nicotine addiction, potentially reducing the desire to smoke and helping with smoking cessation.
Surinabant is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol SNY. Sanofi is conducting clinical trials to evaluate the safety and efficacy of surinabant as a treatment for smoking cessation.
Surinabant is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study. The drug is still investigational and has not received FDA approval or any other regulatory approval for smoking cessation.
Surinabant has one completed clinical trial, identified as NCT00432575, titled "Efficacy and Safety of Surinabant Treatment as an Aid to Smoking Cessation (SURSMOKE)". This Phase 2 study enrolled 810 participants across multiple European countries, including Belgium, France, Germany, Italy, Norway, Spain, Sweden, and Switzerland.
Surinabant is a distinct investigational compound and is not known to be the same as any other marketed drug. It is a selective CB1 receptor antagonist, which differentiates it from other smoking cessation aids that work through different mechanisms, such as nicotine replacement therapies or varenicline.